Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors

Monday, November 18, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics has appointed Colin Bond as a non-executive Director and Chairman of the Audit Committee. Bond brings over 30 years of finance experience, including 15 years as CFO at various biopharmaceutical companies. His extensive background is expected to strengthen Agomab's financial oversight and strategic direction.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a seasoned finance professional to the board.
  • Colin Bond has over three decades of experience in finance.
  • His background includes significant roles in biopharmaceutical companies.

Full Press Release Details

Antwerp, Belgium, November 18, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany and the US

Frequently Asked Questions

Who has been appointed to Agomab's Board of Directors?

Colin Bond has been appointed as a non-executive Director.

What position will Colin Bond hold at Agomab?

He will serve as the Chairman of the Audit Committee.

What is Colin Bond's experience in finance?

He has over three decades of finance experience in international corporations.

How long has Colin Bond worked as a CFO?

He has fifteen years of experience as a CFO in biopharmaceutical companies.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab Colin Bond Board of Directors Audit Committee biopharmaceutical
Last updated: Nov 18, 2024

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →